Halozyme's insulin effectively controls glucose in 2 trials

10/23/2011 | Bloomberg Businessweek

Data from two midstage clinical trials show that Halozyme Therapeutics' insulin PH20 was as effective as Eli Lilly and Co.'s Humalog in controlling blood glucose levels in patients with type 1 and type 2 diabetes. Halozyme is seeking partnerships and opportunities worldwide to make its insulin available.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA